ANGO News and Press, AngioDynamics Inc. From 03/28/19

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration (FDA) granted an expanded 510(k) clearance for the OARtr...

The following slide deck was published by AngioDynamics, Inc. in conjunction with this Read more ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2019 before the market open...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Michael C. Greiner, Executive Vice Presid...

NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heron Therapeutics, Inc. (NASDAQ:HRTX), IDACORP, Inc. (NYSE:IDA), Star Bu...

AngioDynamics ( ANGO ) Q1 results : Revenues: $85.3M (-0.1%). More news on: AngioDynamics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

AngioDynamics (NASDAQ: ANGO ): Q1 Non-GAAP EPS of $0.16 misses by $0.02 ; GAAP EPS of -$0.01. More news on: AngioDynamics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Fiscal 2019 First Quarter Highlights Net sales of $85.3 million, flat versus prior year Gross margin expanded 380 basis points year over year to 52.1% GAAP EPS of $(0.01) per share; adjusted EPS of $0.16 per share Cash used in operations of $8.9 million; capital e...